MITOXANTRONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mitoxantrone Hydrochloride, and when can generic versions of Mitoxantrone Hydrochloride launch?
Mitoxantrone Hydrochloride is a drug marketed by Fresenius Kabi Oncol, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, Mylan Labs Ltd, and Rising. and is included in seven NDAs.
The generic ingredient in MITOXANTRONE HYDROCHLORIDE is mitoxantrone hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mitoxantrone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mitoxantrone Hydrochloride
A generic version of MITOXANTRONE HYDROCHLORIDE was approved as mitoxantrone hydrochloride by FRESENIUS KABI USA on April 11th, 2006.
Summary for MITOXANTRONE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 377 |
Patent Applications: | 1,329 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MITOXANTRONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MITOXANTRONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pediatric Oncology Experimental Therapeutics Investigators' Consortium | Phase 1/Phase 2 |
Lucile Packard Children's Hospital Foundation | Phase 1/Phase 2 |
Stanford University | Phase 1/Phase 2 |
Pharmacology for MITOXANTRONE HYDROCHLORIDE
Drug Class | Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |